TD Cowen Reiterates Buy Rating for Stevanato Group

TD Cowen has reiterated its buy rating for Stevanato Group S.p.A. (NYSE: STVN) on June 16, 2026, maintaining a price target of $25. This move reflects the firm's confidence in the company's future performance.

Stevanato Group Stock Snapshot

Shares of NYSE:STVN are currently trading near $16.63. Stevanato Group boasts a market capitalization of approximately $4.54 billion and has a P/E ratio of 28.19. The company's stock has a 52-week low of $12.89 and a high of $28.00, with a 50-day moving average of $16.92 and a 200-day moving average of $19.80. The firm maintains a current ratio of 1.63 and a quick ratio of 1.11, alongside a debt-to-equity ratio of 29.43.

Recent Earnings

Stevanato Group reported revenues of $1.20 billion, reflecting a growth rate of 6.6%. The company's earnings per share (EPS) stand at $0.59, with a net margin of 11.75% and a return on equity (ROE) of 9.59%. The next earnings date is anticipated on August 4, 2026.

Dividend

The company pays an annual dividend rate of $0.06 per share, yielding 0.37% with a dividend payout ratio of 10.59%.

Insider Buying and Selling at Stevanato Group S.p.A.

Recent insider activity includes sales by Mauro Stocchi, who sold 12,888 shares on June 12, 2025, at an average price of $21.56, and Franco Moro, who sold 13,500 shares on June 14, 2023, at a price of $30.85.

Analysts Set New Price Targets

On June 16, 2026, TD Cowen reiterated its buy rating for Stevanato Group with a price target of $25. Earlier, on June 2, 2026, Wolfe Research assumed coverage with a buy rating and a $21 target. Morgan Stanley maintained a hold rating with a $19 target on March 6, 2026, while Citigroup and Keybanc both maintained buy ratings with targets of $26 and $32, respectively, on March 5, 2026. The consensus recommendation is a buy, with an average target price of $24.39 based on nine analyst opinions.

About Stevanato Group S.p.A.

Stevanato Group S.p.A. is a healthcare company based in Piombino Dese, Italy. It designs and produces products for the biopharma and healthcare industries, operating in sectors like medical instruments and supplies. The company offers a range of solutions including drug containment and delivery systems, diagnostic solutions, and engineering services. Founded in 1949, it employs over 6,000 people and serves a global market.

Bottom Line

TD Cowen's reiterated buy rating for Stevanato Group suggests continued optimism about the company's prospects. With a strong market position and recent earnings growth, Stevanato remains a company to watch in the healthcare sector. As always, investors should remember that analyst ratings are based on past data and projections, which may not reflect future performance.